Effect of oral beta interferon on subsequent immune responsiveness

Annals of the New York Academy of Sciences

Volumn 778, Issue , 1996, Pages 145-155

  Nelson, Patricia A ^a   Akselband, Yevgenya ^a   Dearborn, Susan M ^a   Al Sabbagh, Ahmad ^a   Jane Tian, Z ^a   Gonnella, Patricia A ^b   Zamvil, Scott S ^b   Chen, Youhai ^b   Weiner, Howard L ^b  

^a AutoImmune Inc   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; MYELIN; MYELIN BASIC PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; DISEASE SEVERITY; FEMALE; IMMUNOLOGICAL TOLERANCE; INCIDENCE; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; T LYMPHOCYTE;

EID: 0029966563     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1996.tb21123.x     Document Type: Article

References (27)

1. WEINER, H. L., A. FRIEDMAN, A. MILLER, S. J. KHOURY, A. AL-SABBAGH, L. SANTOS, M. SAYEGH, R. B. NUSSENBLATT, D. E. TRENTHAM & D. A. HAFLER. 1994. Oral tolerance: Immunologic mechanisms and treatment of animals and human organ specific autoimmune diseases by oral administration of autoantigens. Annu. Rev. Immunol. 12: 809-837.
2. ZHANG, Z. & J. MICHAEL. 1990. Orally inducible immune unresponsiveness is abrogated by IFN-γ treatment. J. Immunol. 144: 4163-4165.
3. KHOURY, S. J., O. LIDER, A. AL-SABBAGH & H. L. WEINER. 1990. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. III. Synergistic effect of lipopolysaccharide. Cell. Immunol. 131: 302-310.
4. KHOURY, S. J., W. W. HANCOCK & H. L. WEINER. 1992. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with down-regulation of inflammatory cytokines and differential upregulation of TGF-β, IL-4 and PGE expression in the brain. J. Exp. Med. 46: 1355-1364.
5. ABREU, S. L. 1982. Suppression of experimental allergic encephalomyelitis by interferon. Immunol. Commun. 11: 1-7.
6. HERTZ, F. & R. DEGHENGHI. 1985. Effect of rat and β-human interferons on hyperacute experimental allergic encephalomyelitis in rats. Agents Actions: 16: 397-403.
7. BROD, S. A. & D. K. BURNS. 1994. Suppression of relapsing experimental autoimmune encephalomyelitis in the SJL/J mouse by oral administration of type I interferons. Neurology 44: 1144-1148.
8. AL-SABBAGH, A., P. A. NELSON & H. L. WEINER. 1994. Beta interferon enhances oral tolerance to MBP and PLP in experimental autoimmune encephalomyelitis. Neurology (abstract) 44 (Suppl 2): A242.
9. DEIBLER, G. E., L. F. BOYD & M. W. KIES. 1984. Proteolytic activity associated with purified myelin basic protein. Experimental allergic encephalomyelitis: A useful model for multiple sclerosis. 249-256. Alan R. Liss, Inc. New York.
10. HIGGINS, P. & H. L. WEINER. 1988. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments. J. Immunol. 140: 440-445.
11. WEINER, H. L. 1994. Oral tolerance. Proc. Natl. Acad. Sci. USA 91: 10762-10765.
12. GROUP, T. I. M. S. S. 1993. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 655-661.
13. ARNASON, B. G. W. 1993. Interferon beta in multiple sclerosis. Neurology 43: 641-643.
14. PATY, D. W. 1994. The interferon-β1b clinical trial and its implications for other trials. Ann. Neurol. 36: S113-S114.
15. FAULDS, D. & P. BENFIELD. 1994. Interferon beta-lb in multiple sclerosis: An initial review of its rationale for use and therapeutic potential. Clin. Immunother. 1: 79-87.
16. WEINSTOCK-GUTTMAN, B., R. M. RANSOHOFF, R. P. KINKEL & R. A. RUDICK. 1995. The interferons: Biological effects, mechanisms of action, and use in multiple sclerosis. Ann. Neurol. 37: 7-15.
17. NORONHA, A., A. TOSCAS & M. A. JENSEN. 1990. Interferon beta augments suppressor cell function in multiple sclerosis. Ann. Neurol. 27: 207-210.
18. RUDICK, R. A., C. S. CARPENTER, D. L. COOKFAIR, V. K. TUOHY & R. M. RANSOHOFF. 1993. In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon beta. Neurology 43: 2080-2087.
19. PANITCH, H. S., J. S. FOLUS & K. P. JOHNSON. 1987. Recombinant beta-interferon inhibits gamma interferon production in multiple sclerosis. Ann. Neurol. 22: (abstract) 139.
20. NORONHA, A., A. TOSCAS & M. A. JENSEN. 1991. IFN-beta down-regulates IFN-gamma production by activated T cells in MS. Neurology 41(suppl. 1): (abstract) 219.
21. CUMMINS, J. M., M. B. TOMPKTNS, R. G. OLSEN, W. A. TOMPKINS & M. G. LEWIS. 1988. Oral use of human alpha interferon in cats. J. Biol. Response Modif. 7: 513-523.
22. YOUNG, A. S. & J. M. CUMMINS. 1990. The history of interferon and its use in animal therapy. East Afr. Med. J. 67: SS.31-SS.63.
23. MILLER, A., O. LIDER, A. B. ROBERTS, M. B. SPORN & H. L. WEINER. 1992. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of TGFβ after antigen-specific triggering. Proc. Natl. Acad. Sci. USA 89: 421-425.
24. FRIEDMAN, A. & H. L. WEINER. 1994. Induction of anergy or active suppression following oral tolerance is determined by frequency of feeding and antigen dosage. Proc. Natl. Acad. Sci. USA 91: 6688-6692.
25. CHEN, Y., V. K. KUCHROO, J.-I. INOBE, D. A. HAFLER & H. WEINER. 1994. Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalitis. Nature 265: 1237-1240.
26. PANITCH, H. S., R. L. HIRSCH, J. SCHINDLER & K. P. JOHNSON. 1987. Treatment of multiple sclerosis with gamma interferon: Exacerbations associated with activation of the immune system. Neurology 37: 1097-1102.
27. ARNASON, B. G. W., M. JENSEN, A. LLEDO & A. DAYAL. 1995. Interferon β (INFβ) induction in multiple sclerosis increases interferon γ(INFγ)-secreting cells. Neurology (abstract) 45 (Suppl. 4): A437.